1223573-53-2

Basic information

• Product Name: tert-Butyl 1-thia-6-azaspiro[3.3]heptane-6-carboxylate
• Synonyms: tert-Butyl 1-thia-6-azaspiro[3.3]heptane-6-carboxylate
• CAS NO: 1223573-53-2
• Molecular Formula: C₁₀H₁₇NO₂S
• Molecular Weight: 215.31248
• Mol File: 1223573-53-2.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: tert-Butyl 1-thia-6-azaspiro[3.3]heptane-6-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-Butyl 1-thia-6-azaspiro[3.3]heptane-6-carboxylate(1223573-53-2)
• EPA Substance Registry System: tert-Butyl 1-thia-6-azaspiro[3.3]heptane-6-carboxylate(1223573-53-2)

Safety Data

• Hazardous Substances Data: 1223573-53-2(Hazardous Substances Data)

Usage

General Description

Tert-butyl 1-thia-6-azaspiro[3.3]heptane-6-carboxylate is a complex organic chemical compound with a unique structure. It is a derivative of spirocyclic compounds, containing a spiro[3.3]heptane core with a thiol group and an ester functional group. The tert-butyl group is a bulky and sterically hindered substituent, which can affect the compound's reactivity and stability. This chemical may have potential applications in pharmaceuticals or materials science due to its unique spirocyclic structure, which could contribute to the development of new drugs or materials with specific properties. However, further research is needed to fully understand its potential uses and properties.

Upstream product

• 1223573-52-1 tert-butyl 3-(acetylsulfanyl)-3-(2-oxoethyl)azetidine-1-carboxylate 
• 1223573-23-6 tert-butyl 3-(2-oxomethylene)azetidine-1-carboxylic acid 
• 398489-26-4 tert-butyl 3-oxoazetidine-1-carboxylate 
• 1223573-24-7 tert-butyl 3-(2-hydroxyethyl)-3-mercaptoazetidine-1-carboxylate 

Downstream Products

• 1223573-25-8 tert-butyl 1-thia-6-azaspiro[3.3]heptane-6-carboxylate 1,1-dioxide 
• 1352546-75-8 1-thia-6-azaspiro[3.3]heptane-1,1-dioxide 
• 1427358-97-1 1-thia-6-azaspiro[3.3]heptane 1,1-dioxide hydrochloric acid salt 

Relevant articles and documents

TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS

The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of the CBP/p300 family of bromodomains. For instance, the disclosure is concerned with compounds and compositions for inhibition of the CBP/p300 family of bromodomains, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of CBP/p300 family of bromodomains, and methods of synthesis of these compounds.

GPR40 AGONISTS IN ANTI-DIABETIC DRUG COMBINATIONS

Disclosed are compositions comprising (a) a GPR40 agonist and (b) an SGLT2 inhibitor, and methods for treating of disorders that are affected by the modulation of the GPR40 receptor and SGLT2 transporter. Such GPR40 compounds are represented by Formula (I) as follows: wherein ring W, R1, R2, R3, R5, R6, A, and Z, are defined herein.

SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS

Provided herein are novel substituted bicyclic aza-heterocycle sirtuin- modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin- modulating compound in combination with another therapeutic agent.